Literature DB >> 23588953

Characteristics of basal cytokeratin expression in breast cancer.

Alaa T Alshareeda1, Daniele Soria, Jonathan M Garibaldi, Emad Rakha, Christopher Nolan, Ian O Ellis, Andrew R Green.   

Abstract

Breast cancer is recognised to be a heterogeneous disease and the second most common cause of morbidity and mortality worldwide in women. Basal-like breast cancer (BLBC) is associated with aggressive characteristics including development of recurrent disease and reduced survival. BLBC has been defined in some studies as tumours lacking both oestrogen receptor and progesterone receptor protein expression. Gene expression studies have shown that these tumours are also associated with expression of basal-type cytokeratins, the phenotypic patterns of basal cytokeratin expression in BLBC have not been widely studied. A well-characterised series of 995 invasive breast cancers with a long-term follow up were investigated using immunohistochemical staining for four basal cytokeratins (CK5, CK5/6, CK14 and CK17). The data were analysed using univariate and clustering analysis. As a result BLBC, as defined by negativity for ER and HER2 showed variable positivity for basal cytokeratin expression: 61.7 % CK5, 50.5 % CK5/6, 24.2 % CK14 and 23 % CK17. These characteristics were associated with poor outcome characteristics including high histological grade, mitosis, pleomorphism and tumour size >1.5 cm. CK5 positivity was more associated with ER(-), PgR(-), TN and double ER(-)PgR(-), than the other cytokeratins. Four different clusters of basal cytokeratin expression patterns were identified: (1) negativity for all basal cytokeratins, (2) CK5(+)/CK17(-), (3) CK5(-)/CK17(+) and (4) CK5(+)/CK17(+). These patterns of basal cytokeratin expression associated with differences in patient outcome, clusters 1 and 3 showed better outcomes than cluster 4 and 2, with cluster 2 having the poorest prognosis. In conclusion, four basal cytokeratin expression patterns were identified in human breast cancer using unsupervised clustering analysis and these patterns are associated with differences in patient outcome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588953     DOI: 10.1007/s10549-013-2518-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice.

Authors:  Amanda S Peretti; Dayna Dominguez; Martha M Grimes; Helen J Hathaway; Eric R Prossnitz; Melanie R Rivera; Angela Wandinger-Ness; Donna F Kusewitt; Laurie G Hudson
Journal:  Am J Pathol       Date:  2017-11-21       Impact factor: 4.307

2.  An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis.

Authors:  Hiroyuki Katayama; Clayton Boldt; Jon J Ladd; Melissa M Johnson; Timothy Chao; Michela Capello; Jinfeng Suo; Jianning Mao; JoAnn E Manson; Ross Prentice; Francisco Esteva; Hong Wang; Mary L Disis; Samir Hanash
Journal:  Cancer Res       Date:  2015-06-18       Impact factor: 12.701

3.  fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions.

Authors:  Maria Soares; Assunção N Correia; Mariana R Batista; Jorge Correia; Fernando Ferreira
Journal:  Animals (Basel)       Date:  2022-06-21       Impact factor: 3.231

4.  Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

Authors:  Alice Chung; Michael Choi; Bing-chen Han; Shikha Bose; Xiao Zhang; Lali Medina-Kauwe; Jessica Sims; Ramachandran Murali; Michael Taguiam; Marian Varda; Rachel Schiff; Armando Giuliano; Xiaojiang Cui
Journal:  Clin Breast Cancer       Date:  2015-06-19       Impact factor: 3.225

5.  Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?

Authors:  Abdelfattah M Attallah; Mohamed El-Far; Mohamed M Omran; Sanaa O Abdallah; Mohamed A El-Desouky; Ibrahim El-Dosoky; Mohamed A Abdelrazek; Ahmed A Attallah; Mohamed A Elweresh; Gamal E Abdel Hameed; Hadil A Shawki; Karim S Salama; Ahmed M El-Waseef
Journal:  Tumour Biol       Date:  2014-07-30

6.  Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.

Authors:  Ke-Da Yu; Yi-Zhou Jiang; Shuang Hao; Zhi-Ming Shao
Journal:  BMC Med       Date:  2015-10-05       Impact factor: 8.775

7.  Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.

Authors:  Pascal Jézéquel; Delphine Loussouarn; Catherine Guérin-Charbonnel; Loïc Campion; Antoine Vanier; Wilfried Gouraud; Hamza Lasla; Catherine Guette; Isabelle Valo; Véronique Verrièle; Mario Campone
Journal:  Breast Cancer Res       Date:  2015-03-20       Impact factor: 6.466

8.  Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment.

Authors:  Yvonne S Ziegler; James J Moresco; Patricia G Tu; John R Yates; Ann M Nardulli
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

9.  Clinicopathologic features of triple negative breast cancers: an experience from Pakistan.

Authors:  Atif Ali Hashmi; Muhammad Muzzammil Edhi; Hanna Naqvi; Naveen Faridi; Amna Khurshid; Mehmood Khan
Journal:  Diagn Pathol       Date:  2014-02-28       Impact factor: 2.644

10.  Gene Expression Profiling of Breast Cancer Brain Metastasis.

Authors:  Ji Yun Lee; Kyunghee Park; Eunjin Lee; TaeJin Ahn; Hae Hyun Jung; Sung Hee Lim; Mineui Hong; In-Gu Do; Eun Yoon Cho; Duk-Hwan Kim; Ji-Yeon Kim; Jin Seok Ahn; Young-Hyuck Im; Yeon Hee Park
Journal:  Sci Rep       Date:  2016-06-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.